尿胰蛋白酶抑制剂对先兆早产患者妊娠过程影响的再评估：一项单中心回顾性研究
Re-evaluation of Urinary Trypsin Inhibitor on Pregnancy Course in Patients with Threatened Preterm Delivery: A Single-Center Retrospective Study.
作者信息
Komatsu Hiroaki, Taniguchi Fuminori, Harada Takashi, Nakaso Takaya, Nishimura Noriko, Tsukihara Satoru, Sarugami Masako, Harada Tasuku, Kanamori Yasunobu
机构信息
Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital, Yamaguchi 753-0092, Japan.
Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
出版信息
Yonago Acta Med. 2019 Jun 20;62(2):204-210. doi: 10.33160/yam.2019.06.005. eCollection 2019 Jun.
BACKGROUND
We evaluated the necessity of urinary trypsin inhibitor for patients with threatened premature labor.
METHODS
We enrolled 146 women with singleton pregnancies who were treated for threatened premature labor as inpatients. The uterine cervical length of each patient was ≤ 25 mm at 22-35 weeks of gestation on transvaginal ultrasonography. The patients were divided into two groups: the urinary trypsin inhibitor group (91 patients treated with urinary trypsin inhibitor daily) or non-urinary trypsin inhibitor group (55 patients not treated with urinary trypsin inhibitor). The childbirth outcomes were retrospectively assessed.
RESULTS
The median cervical length measured on the day of admission was almost similar between the urinary trypsin inhibitor and non-urinary trypsin inhibitor groups. Depending on the symptoms of uterine contractions, we determined whether ritodrine hydrochloride and/or magnesium sulfate would be appropriate for treatment. The median gestational week at birth was 38 weeks in the urinary trypsin inhibitor group, and no obvious differences were observed when compared with the non-urinary trypsin inhibitor group. With regard to birth weight, no significant difference was found between the two groups (urinary trypsin inhibitor group, 2776 g; non-urinary trypsin inhibitor group, 2800 g).
CONCLUSION
Our data showed no significant beneficial effects of urinary trypsin inhibitor in the maternal course and delivery outcomes.
背景
我们评估了尿胰蛋白酶抑制剂对先兆早产患者的必要性。
方法
我们纳入了146名单胎妊娠的住院治疗先兆早产的女性。经阴道超声检查显示，每位患者在妊娠22 - 35周时宫颈长度≤25毫米。患者被分为两组：尿胰蛋白酶抑制剂组（91例患者每日接受尿胰蛋白酶抑制剂治疗）和非尿胰蛋白酶抑制剂组（55例患者未接受尿胰蛋白酶抑制剂治疗）。对分娩结局进行回顾性评估。
结果
尿胰蛋白酶抑制剂组和非尿胰蛋白酶抑制剂组入院当天测量的宫颈长度中位数几乎相似。根据子宫收缩症状，我们确定盐酸利托君和/或硫酸镁是否适合治疗。尿胰蛋白酶抑制剂组的中位出生孕周为38周，与非尿胰蛋白酶抑制剂组相比未观察到明显差异。关于出生体重，两组之间未发现显著差异（尿胰蛋白酶抑制剂组为2776克；非尿胰蛋白酶抑制剂组为2800克）。
结论
我们的数据表明尿胰蛋白酶抑制剂在产妇病程和分娩结局方面没有显著的有益作用。
Zotero 插件